A limitation of the pMHC multimer technology is that the MHC allotypes of the patient need to be known and the many potential antigenic epitopes need to be accurately predicted to limit pMHC multimers libraries to reasonable workloads and at the same time also match the often limited availability of tumor patients’ blood samples and the urgent medical need. The gene discussed is HLA-C; the disease is neoplasm.